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Abstract
Background: The latent membrane protein-1 (LMP1) encoded by Epstein-Barr virus (EBV) is an oncoprotein which acts 
by constitutive activation of various signalling pathways, including NF-κB. In so doing it leads to deregulated cell 
growth intrinsic to the cancer cell as well as having extrinsic affects upon the tumour microenvironment. These 
properties and that it is a foreign antigen, lead to the proposition that LMP1 may be a good therapeutic target in the 
treatment of EBV associated disease. LMP1 is expressed in several EBV-associated malignancies, notably in Hodgkin's 
lymphoma and nasopharyngeal carcinoma (NPC). However, the viral protein is only detected in approximately 30%-
50% of NPC samples, as such its role in carcinogenesis and tumour maintenance can be questioned and thus its 
relevance as a therapeutic target.
Results: In order to explore if LMP1 has a continuous function in established tumours, its activity was inhibited through 
expression of a dominant negative LMP1 mutant in tumour cell lines derived from transgenic mice. LMP1 is the tumour 
predisposing oncogene in two different series of transgenic mice which separately give rise to either B-cell lymphomas 
or carcinomas. Inhibition of LMP1 activity in the carcinoma cell lines lead to a reduction in clonagenicity and clone 
viability in all of the cell lines tested, even those with low or below detection levels of LMP1. Inhibition of LMP1 activity 
in the transgenic B-cell lines was incompatible with growth and survival of the cells and no clones expressing the 
dominant negative LMP1 mutant could be established.
Conclusions: LMP1 continues to provide a tumour cell growth function in cell lines established from LMP1 transgenic 
mouse tumours, of both B-cell and epithelial cell origin. LMP1 can perform this function, even when expressed at such 
low levels as to be undetectable, whereby evidence of its expression can only be inferred by its inhibition being 
detrimental to the growth of the cell. This raises the possibility that LMP1 still performs a pro-oncogenic function in the 
50% to 70% of NPC tumours wherein LMP1 protein expression cannot be detected. This reinforces the basis for 
pursuing LMP1 as a therapeutic target in EBV associated LMP1-expressing malignancies.
Background
Epstein-Barr Virus (EBV) is a human herpes virus which
is associated with a number of malignant diseases reflect-
ing the viral tropism primarily to B-cells but also to epi-
thelial cells and rarely other cell types. The EBV-
associated B-cell cancers include endemic Burkitt's lym-
phoma (BL), a subset of Hodgkin's disease (HD) cases and
lymphoid tumours arising in immunosuppressed
patients; the epithelial cell cancers include nasopharyn-
geal carcinoma (NPC) and a proportion of gastric can-
cers. EBV shows a different but typical pattern of latent
gene expression in each of these malignancies, from the
most restricted pattern of viral expression in BL, to
expression of all of the viral latent genes in post-trans-
plant lymphoproliferative disease. NPC and HD biopsies
show an intermediate pattern of viral gene expression
involving EBNA-1, latent membrane proteins-1 and -2A
(LMP1 and LMP2A), EBERs and the BART micro RNAs
[1].
LMP1 exhibits properties of a classical oncoprotein,
inducing promotion of cell growth and inhibition of
apoptosis in a variety of cell types in vitro [2]. In addition
it has been demonstrated to contribute to both B-cell and
epithelial cell tumourigenesis in vivo in transgenic mice
[3-5]. LMP1 achieves its wide ranging phenotypic effects
through the activation of multiple signalling cascades. It
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activates the NF-κB, JNK and JAK/STAT pathways
through direct interaction with pathway intermediary
proteins [6]. As a consequence of the gene expression
changes induced, for example affecting EGFR and it's
ligands [7,8], further pathways are triggered including the
ERK/MEK and p38/MAPK pathways. As such, LMP1 is
considered as the primary oncogene of the virus and a
likely candidate in driving the development of several of
the EBV associated malignancies.
Significant progress has been made in recent years in
cancer therapeutics in the design of inhibitory molecules
that impact relevant signalling pathways, for example B-
Raf inhibition in the treatment of melanoma [9]. As a for-
eign antigen that constitutively activates multiple path-
ways, LMP1 represents a good therapeutic target in the
treatment of EBV associated malignancies. Moreover,
while LMP1 activates growth pathways within the cancer
cell, in deregulating NF-κB it also impacts a seminal path-
way in inflammation programmes and thus potentially,
factors in the tumour microenvironment. Therefore tar-
geting LMP1 could affect both intrinsic and extrinsic fac-
tors essential to tumour growth. LMP1 expression has
been confirmed by immunohistochemical studies in
EBV-associated HD. However, detection of LMP1 protein
in NPC biopsies is highly variable, with only between 30%
to 50% of tumours showing clear expression [10] despite
the detection of LMP1 RNA in most samples. Indeed it
has been shown that the BART micro RNAs of the virus,
which are abundantly expressed in NPC, negatively regu-
late LMP1 protein expression [11]. This raises some
uncertainty about the role of LMP1 in the genesis of NPC
and particularly any tumour maintenance function, espe-
cially in those tumours where expression cannot be
detected. This in turn poses the question of whether
LMP1 is a rational therapeutic target.
Inhibition of LMP1 expression by siRNA in an EBV
positive NPC derived cell line C666-1, which clearly
expresses LMP1, was found to induce cell cycle arrest and
enhance the sensitivity of the cells to cisplatin [12]. This
observation is encouraging with respect to LMP1 as a
potential therapeutic target. However it is unknown at
present if this finding will be limited to those NPC
tumours with high LMP1 expression. In this study we
sought to evaluate the impact of LMP1 inhibition in mul-
tiple cell lines, of both epithelial and B-cell origin where
LMP1 was the driving oncogene in the development of
the tumour. It is notoriously difficult to derive cell lines
from NPC and HD tumours and as a consequence there
are few lines available. To this end we used cell lines
derived from tumours from transgenic mice where LMP1
was the predisposing oncogene. These lines were also
used with a view to future in vivo drug testing. In all of
the LMP1 transgenic cell lines tested, inhibition of LMP1
activity inhibited the growth properties of the cells (to
varying extents in the different lines) surprisingly even in
those where LMP1 protein expression was not detectable.
Firstly, this demonstrates that even extremely low levels
of LMP1 can continue to provide a growth advantage to
cancer cells and secondly, as a consequence, its inhibition
could be an effective route in the treatment to eliminate
the cells. However in one highly malignant carcinoma cell
line, inhibition of LMP1 lead to the selection of escape
mutants indicating that any treatment targeting LMP1
would be best used as part of a combined therapy regime.
Results
LMP1 expression in transgenic carcinoma and lymphoma 
cell lines
In order to investigate the tumour growth promoting
properties of LMP1 and whether its continued expression
is required in established tumours, carcinomas and B-cell
lymphomas from LMP1 expressing transgenic mice were
established in culture.
C a r c i n o m a s  w e r e  i n d u c e d  i n  t r a n s g e n e  p o s i t i v e  a n d
negative sibling controls (NSC) in the transgenic PyLMP1
line 53 (PyLMP1.53) [3], by topical treatment with chem-
ical carcinogens [13]. These tumours could be readily
established in culture; some retained a cuboidal,
squamous morphology while others developed a spindle
morphology with more transformed growth characteris-
tics (additional files 1&2, supplementary table S1). LMP1
was difficult to extract from these epithelial cells (as with
transgenic skin tissue [5]), suggesting an association with
the cytoskeleton and necessitating the use of a urea
extraction protocol. LMP1 expression was detected by
immunoprecipitation and western blotting in several, but
not all of the transgene positive carcinoma cell lines
developed (figure 1A). Nevertheless, the cell lines in
which expression could not be detected maintained the
transgene (not shown). There was no apparent correla-
tion between the carcinoma grade, cell line phenotype
and LMP1 expression. For example, cell line 53.278a,
derived from an aggressive spindle cell carcinoma and
showing rapid spindle cell growth in culture (see supple-
mentary information table 1) showed LMP1 expression
a s  d i d  t h e  m o r e  c u b o i d a l  c e l l  l i n e  2 3 4 a  ( w i t h  h i g h e s t
LMP1 expression) derived from a grade 3 carcinoma.
However, with cuboidal cell line 53.226b (grade 1 carci-
noma) and spindle cell line 53.191 (grade 3 carcinoma),
little or no LMP1 expression could be detected.
Lymphomas arise spontaneously in aged mice of the
transgenic line EμLMP1.39 (additional files 1&2, supple-
mentary figure S1) in which LMP1 expression is directed
to the lymphoid compartment [3]. Cell line 39.415 is a
murine B-cell line developed from a lymphoma from
transgenic line EμLMP1.39 (additional files 1&2, supple-
mentary figure S2) showing readily detectable LMP1
expression (figure 1B). LMP1 expression in the 39.415 cellHannigan and Wilson Molecular Cancer 2010, 9:184
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line is approximately 30-fold lower than the human BL
cell line Raji (which harbours 50 to 60 copies of the EBV
genome per cell). Cell line 3959.48 was established from a
B-cell lymphoma arising in a bi-transgenic mouse har-
bouring EμLMP1 and EμEBNA-1 transgenes. It expresses
readily detectable EBNA1 [14] and low levels of LMP1,
with the latter at least 300-fold lower (on a per cell basis)
than cell line 39.415 (figure 1B). Cell line 39.415 tends to
grow in large clumps in culture, while 3959.48 grows as a
single cell suspension or in small clumps, possibly reflect-
ing LMP1 induced homotypic adhesion [15] and their rel-
ative levels of LMP1.
Inhibition of LMP1 in the transgenic carcinoma cell lines
In order to inhibit LMP1 activity a dominant negative
mutant of LMP1 which is defective in the LMP1 induced
signalling pathways, termed LMP1AAAG, fused to GFP
[16] denoted here as GFPdnLMP1 (or dnL as designation
for transfected cells and clones) was introduced into the
transgenic carcinoma cell lines. Using the parental GFP
expression vector as control, six PyLMP1 transgenic car-
cinoma cell lines were transfected and one transgene neg-
ative control (figure 2, table 1). Following 2 weeks of
plasmid selection, in all PyLMP1 cell lines the number of
clones derived from pGFPdnLMP1 transfection was less
than that from pGFP transfection, ranging from a 2.4 fold
difference for (line 53.278a) to an 11 fold difference (line
53.278b) and in one cell line (53.204) no GFPdnLMP1
clones emerged. Furthermore, the pGFPdnLMP1 trans-
fected clones tended to be smaller and less dense than the
pGFP transfectants (figure 2). In contrast, clones of
equivalent size and density were obtained in equal num-
bers for the two plasmids in the transgene-negative carci-
noma cell line 53.217 (figure 2, table 1). This
demonstrates that the pGFPdnLMP1 and pGFP plasmids
were not toxic and of equal impact (if any) in an LMP1
negative carcinoma cell line. However, the data suggest
that in all of the PyLMP1 transgenic cell lines, even those
where LMP1 expression was low or undetectable (cell
lines 53.278b, 53.226b, 53.191), dnLMP1 is inhibitory to
clonagenicity. Clones derived in this manner were either
c u l t u r e d  a s  a  p o o l  o r  i n d i v i d u a l l y  i s o l a t e d  f o r  f u r t h e r
analysis from the transgene negative cell line 53.217 and
two PyLMP1 positive cell lines 53.234a and 53.278a.
Only one of six GFPdnLMP1 53.234a clones isolated
could be established (referred to as 53.234dnL-1) while all
six 53.217dnL clones were expanded. 10/12 clones of
53.278adnL were also established. This again reflects the
inhibitory effect of dnLMP1 upon the clonagenicity of
cell line 53.234a and to a lesser extent with cell line
53.278a. GFPdnLMP1 expression was confirmed in the
single 53.234dnL-1 clone and in 3/3 tested 53.217dnL
clones (figure 3A). For 53.278adnL clones, 5/10 showed
clear GFPdnLMP1 expression (figure 3B and 3C and
additional files 1&2, supplementary figure S3). GFP
expression was confirmed in the majority of control
pGFP transfected clones tested (figure 3).
The single 53.234dnL-1 clone established must have
selectively overcome the inhibitory effect of dnLMP1 to
some degree. In order to explore this further, clone
Table 1: Clonagenicity of the epithelial cell lines with dnLMP1
cell line transgene colonies per μg of DNA colony ratio
status pGFPdnLMP1 pGFP pGFPdnLMP1:pGFP
53.217 - 164 170.4 1 : 1.0
53.234a + 8.8 41.6 1 : 4.7
53.204 + 04 . 2-
53.191 + 14 42 1 : 3.0
53.226b + 1.6 6 1 : 3.8
53.278a + 46 112 1 : 2.4
53.278b + 1.2 13.2 1 : 11.0
The various cell lines (as shown) were transfected and grown for two weeks under G418 selection before fixing and staining with crystal violet 
(details in the legend to figure 2). The number of colonies per μg of DNA and the ratio of colonies for the GFPdnLMP1:GFP plasmids are 
tabulated.Hannigan and Wilson Molecular Cancer 2010, 9:184
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53.234dnL-1 was compared to clone 53.217dnL-3 (with
highest expression of the 53.217 clones) for cell growth,
against the parental cell lines and clones expressing only
GFP. With the transgene negative cell line 53.217, clones
expressing GFP or GFPdnLMP1 showed identical growth
curves compared to the parental cell line (figure 4). How-
ever, the PyLMP1 positive clone 53.234dnL-1 showed sig-
nificantly slower growth compared to both the parental
cell line and GFP transfectants (figure 4). These data sug-
gest that despite clone 53.234dnL-1 having been estab-
lished under the selective pressure of dnLMP1
expression, i.e. inhibition of LMP1, the growth is never-
theless impaired compared to the parental cell line. Thus
any genetic or epigenetic changes that have occurred in
this cell clone to allow it to become established have not
fully compensated for the blockade of LMP1 activity in
cell growth.
We then examined the aggressive spindle cell line
53.278a which had shown least dependency upon LMP1
in the clonagenicity assay (table 1). Growth of three of the
clones showing highest GFPdnLMP1 expression
(53.278adnL-4, -6 and -8) were compared to the parental
cell line and the highest GFP expressing control clone.
The GFP clone 53.278aGFP-5 showed an identical
growth rate to the parental cell line, while all three
dnLMP1 clones revealed significantly accelerated growth
rates (figure 4). These data demonstrate that enforced
dnLMP1 expression in this cell line has selected for more
rapidly growing clones presumably independent of LMP1
activity. The clone with highest GFPdnLMP1 expression,
clone 53.278dnL-8 was assessed for tumourigenicity
compared to the parental cell line, using syngeneic recipi-
ent mice. The clone retained the tumourigenic phenotype
and in 3/4 subsequently derived tumours GFPdnLMP1
expression was maintained (additional files 1&2, supple-
mentary figure S4).
Inhibition of LMP1 in the transgenic B-cell lines
Inhibition of LMP1 activity in the tumour derived B-cell
lymphoma cells lines 39.415 and 3959.48 was similarly
assessed by transfection of the GFPdnLMP1 or GFP
expression vectors. The antibiotic selection process was
complete by 3 weeks post transfection at which point the
cell lines were assayed for GFPdnLMP1 and GFP expres-
sion. Cells were harvested at weekly intervals for four
weeks maintaining drug selection. With 39.415 cells, GFP
expression could be detected in the control pGFP trans-
fectants consistently for the four week period (figure 5A).
However while clear GFPdnLMP1 expression was
Figure 1 LMP1 expression in transgenic mouse derived cell lines. 
(A) LMP1 was immunoprecipitated from 300 μg of urea buffer-extract-
ed proteins from seven PyLMP1 transgene-positive line 53 carcinoma 
cell lines and one transgene-negative cell line (as denoted 53.217neg) 
and 100 μg of protein from control cell lines: Raji (EBV +ve, containing 
50-60 copies of EBV) and Ramos (EBV -ve), using the S12 antiserum. Im-
munoprecipitated proteins were separated by 10%SDS-PAGE and 
blotted alongside two total lysate (boiling mix extracted) controls, 
BL2B95-8 (EBV +ve) and BJAB (EBV -ve) (1 × 105 cells each). The blot was 
probed with anti-LMP1 antibody 1G6 followed by goat α-rat IgG HRP. 
The bands corresponding to LMP1 and the immunoglobulin heavy (H) 
and light (L) chains are indicated on the left. (B) Protein was extracted 
from B-cell lines 39.415 and 3959.48 with controls Raji and BJAB (the 
number of cells indicated below each track) using boiling mix and 
samples western blotted for LMP1 using IG6. The transgenic LMP1 
(tgLMP1) is slightly smaller than Raji LMP1 (rLMP1) [3].
A
total 
lysate IP: -LMP1
tgLMP1
H
L
B
104 104 105 105 106 106 107
tgLMP1
rLMP1
Figure 2 GFPdnLMP1 inhibits the clonogenicity of PyLMP1 trans-
genic carcinoma cell lines. Cell lines 53.217 (transgene negative con-
trol) and 53.234a (PyLMP1 transgenic) were transfected with 5 μg of 
either pGFP or GFPdnLMP1 or mock transfected (no DNA) in duplicate. 
After 24 hrs cells were passaged 1 to 8 and cultured for two weeks un-
der G418 selection before fixing and staining with crystal violet. Colony 
numbers for these and further cell lines treated in the same way are 
given in Table 1.
pGFP
pGFPdnLMP1
no DNA
53.217:  control 53.234a: PyLMP1Hannigan and Wilson Molecular Cancer 2010, 9:184
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detected at 3 and 4 weeks post transfection, it disap-
peared from the transfected culture by 5 weeks post
transfection. Similarly, clear green fluorescence could be
seen in the pGFP transfectants (3 weeks post transfec-
tion) but only weak fluorescence in the pGFPdnLMP1
39.415 transfectants (figure 5B). In contrast, green fluo-
rescence in both pGFP and pGFPdnLMP1 transfectants
of the control EBV negative cell line AK31 was clearly vis-
ible (additional files 1&2, supplementary figure S5) and
could consistently be detected by western to at least 12
weeks after transfection (figure 5C). With the 3959.48 cell
line, similarly consistent GFP expression was seen in the
controls, but GFPdnLMP1 expression could barely be
detected in the transfected cultures at 3 weeks post trans-
fection and was not detected by 4 weeks (not shown).
Therefore earlier time points post transfection were
examined. At two days post transfection of 3959.48 cells
strong expression of GFPdnLMP1 was detected which
was considerably reduced by 5 days post transfection and
again only low level expression was detected by 3 weeks
post transfection (despite plasmid selection), while con-
trol GFP expression in this cell line was constant (figure
5C).
Thus, either GFPdnLMP1 expression (unlike GFP
alone) becomes repressed in the 39.415 and 3959.48
transfected cells or those cells expressing the dominant
negative LMP1 protein are lost from the culture. In order
to examine the viability of the GFPdnLMP1 expressing
cells in the transfected, selected cultures, 3959.48 cells at
four weeks post transfection were stained with propid-
ium iodide (PI; apoptotic cells stain with PI while viable
cells exclude the stain) and examined by flow cytometry.
Of the pGFPdnLMP1 transfected cells 0.8% showed GFP
fluorescence, of which 76.3% stained with PI (figure 5D).
In contrast 6% of the pGFP transfected population
showed GFP fluorescence of which 19.1% stained for PI.
This suggests that the GFPdnLMP1 expressing cells were
being eliminated from the population by apoptosis.
In order to look at earlier time points post transfection
further, 39.415 and 3959.48 cells were examined by
microscopy 24 hours after transfection. In these unse-
lected cell populations bright fluorescent cells could
clearly be seen in cultures transfected with both pGFP
and pGFPdnLMP1, however there were fewer apparent in
Figure 3 Expression of GFP and GFPdnLMP1 in transfected carci-
noma cells. Transgene negative control cell lines 53.217 and CarbB, 
and transgenic PyLMP1 cell lines 53.234a and 53.278a, transfected with 
pGFP or pGFPdnLMP1 were sub-cloned to give clones denoted GFP 
and dnL (respectively). Protein samples from each cell line sub-clone 
(indicated by -number) or pool of clones (-p) were examined by west-
ern blotting, sequentially using anti-LMP1 (top of each panel), α-GFP 
(middle) and α-beta-tubulin (bottom), as indicated. (A) 100 μg of pro-
tein extract from sub-clones or pools of clones from the cell lines 
53.217, CarB and 53.234a. (B) and (C) 50 μg protein extract from sub-
clones or pools of clones (pI and PII) from the cell lines 53.278a and 
control CarB. Non-transfected parental cell line (nt).
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Figure 4 Growth curves of GFP and GFPdnLMP1transfected carci-
noma clones. Clones of the transfected cell lines 53.217 (transgene 
negative; left graph), 53.234a (PyLMP1 transgene; middle graph) and 
53.278a (Py LMP1 transgene; right graph) that showed the highest ex-
pression of GFP or GFPdnLMP1 were analysed for growth by neutral 
red assay and compared to the parental cell line in each case. Means of 
the four replicates (with SD) are plotted. Clone 53.234adnL-1 shows 
significantly different values from the parental cell line 53.234a (day 3: 
p < 0.0001, day 4: p < 0.0001, day 5: p < 0.0001, day 6: p = 0.0009). Sim-
ilarly 53.278a clone values differ significantly from the parental 53.278a 
cell line (eg. for clone 53.278adnL-8: day 3: p = 0.0003, day 4: p < 0.0001, 
d5: p = 0.002).Hannigan and Wilson Molecular Cancer 2010, 9:184
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the latter and these often appeared morphologically
unhealthy. In addition there was evidence of cells under-
going apoptosis in the pGFPdnLMP1 cultures (additional
files 1&2, supplementary figure S6). GFP fluorescence in
the transfected transgenic cells was also examined by
flow cytometry. For cell line 39.415, the proportion of
GFP expressing cells from 2 days post transfection to 5
days post transfection did not drop (36.9% to 36.4%). In
contrast, the proportion of GFPdnLMP1 expressing cells
dropped from 28.5% to 1.6% (figure 6). With 3959.48 cells
2 days post transfection, the proportion of GFP express-
ing cells was 6.6% compared to 2.1% for GFPdnLMP1
(figure 6).
These data demonstrate that both transgenic B-cell
lines require the continued action of LMP1 for growth
and survival, even in the cell line 3959.48 where LMP1
expression is very low.
Discussion
In this study we have examined the consequences of
inhibiting LMP1 activity in several cell lines which were
derived from transgenic mice where LMP1 was the driv-
ing oncogene in the tumourigenic process. A dominant
negative mutant of LMP1 which inhibits its signalling
capacity was used with a view to future therapeutic drugs
which might target LMP1 function in a competitive man-
ner . W e have explored the effects of inhibition in cells
from established tumours, not upon cancer development,
to reflect that in the clinical setting treatment is only ini-
tiated in patients with established tumours. Furthermore,
in a number of these cell lines, LMP1 expression was low
or undetectable and its continued function in the tumour
cells was equivocal.
Figure 5 GFPdnLMP1 expression is lost from EμLMP1 transgenic 
B-cell lymphoma cultures. Transgenic EμLMP1 cell lines 39.415 and 
3959.48, along with an EBV negative Akata cell line sub clone (AK31), 
transfected with pGFP or pGFPdnLMP1 were assayed for transfectant 
expression. (A) Protein extract from 5 × 105 39.415 transfected cells 
(and non-transfected control: nt) were examined by western blotting 
sequentially using anti-LMP1 (top panel), α-GFP (middle) and α-beta-
tubulin (bottom), as indicated. Cell aliquots were collected after com-
pletion of selection at 3 weeks post transfection (post-tx) and then at 
weekly intervals (maintaining G418 selective pressure). (B) Bright field 
(left panel) and green fluorescence (right panel) visualized in 
pGFPdnLMP1 (top panel) or pGFP (bottom panel) transfected 39.415 
cells at 3 weeks post transfection. (C) 40 μg of protein extract from 
3959.48 and control AK31 transfected cells (and non-transfected con-
trol: nt) were examined by western blotting sequentially using anti-
LMP1 (top panel), α-GFP (middle) and α-beta-tubulin (bottom), as indi-
cated. Cell aliquots were collected at 2, 5 and 21 days post transfection 
(post-tx) for 3959.48 cells and at 12 weeks post-tx for AK31 cells (all un-
der G418 selection). (D) At four weeks post pGFP or pGFPdnLMP1 
transfection 3959.48 cells stained with propidium iodide (viable cells 
exclude staining, apoptotic cells stain) were analysed by flow cytome-
try, gating on GFP positive fluorescent cells only. Histograms show y 
axis (cell counts) and x axis (FL2-H, PI staining). The percentage of PI 
positive cells (of the GFP positive population) is indicated.
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Figure 6 GFPdnLMP1 expression is not compatible with the sur-
vival of EμLMP1 transgenic B-cell lymphoma lines. Flow cytometric 
analysis of pGFP (left) or pGFPdnLMP1 (right) transfected 39.415 cells 
and 3959.48 cells as indicated. Cells were analysed two days and five 
days post-transfection (under G418 selection), dot plots showing y axis: 
side scatter (SSC) and x axis: FL1-H: green fluorescence (GFP). The gated 
population represents the GFP positive cells with the percentage indi-
cated.
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I n h i b i t i o n  o f  L M P 1  a c t i v i t y  i n  c a r c i n o m a  c e l l  l i n e s
e s t a b l i s h e d  f r o m  L M P 1  t r a n s g e n i c  m i c e  r e s u l t e d  i n
reduced clonagenicity (reflecting growth and survival of
the cells at low density) in all of the cell lines tested. Inter-
estingly, this was even the case in cell lines where LMP1
protein expression could not be detected, suggesting that
there is a low-level (below detection) expression of LMP1
in these cell lines and that it still confers a growth advan-
tage to the cells. This is relevant to NPC where LMP1
RNA can be detected in the majority of tumours but pro-
tein in only 30% to 50% of samples. This raises the possi-
bility that the 50% to 70% of cases in which LMP1 protein
is not detected may nevertheless express functioning
LMP1.
Clonagenicity was not abolished in the carcinoma cell
lines studied here (with the exception of one cell line). To
varying degrees with the different lines, clones could be
established and expression of dnLMP1 was shown for
two LMP1 transgenic positive cell lines. Clone
53.234dnL-1 (derivative of 53.234a) must have undergone
genetic or epigenetic changes to enable its establishment,
but it nevertheless had slower growth characteristics than
the parental cell line. As such, any changes it incurred did
not fully compensate for LMP1 activity in the growth of
the cell. By contrast 53.278adnL clones had more than
compensated, evolving a faster growth pattern than the
parental cell line. This cell line was derived from a spindle
cell tumour, advanced and aggressive in nature and as
such may have already undergone several changes in vivo
to render LMP1 function redundant. One could therefore
speculate that any LMP1 directed therapy with such a
tumour (in the absence of other therapies) would force
progression through selection, leading to drug resistant,
aggressive escape mutants. Nevertheless, such a treat-
ment could still potentially augment cytotoxic drug treat-
ment.
With the cell lines and derived clones developed here
we are now in a position to investigate the critical
changes required in a tumour cell to allow it to overcome
loss of LMP1 function. This knowledge could provide
further targets to be used in combination with any LMP1
directed therapy.
The LMP1 transgenic B-cell lines examined could not
tolerate inhibition of LMP1 activity, even in the 3959.48
cell line with very low LMP1 levels. Expression of
dnLMP1 was either rapidly shut down in the transfected
cells or those expressing cells were lost from the popula-
tion. The kinetics would suggest the latter, as loss of
dnLMP1 expression in the population could be seen after
only a few population doublings, despite selection for
plasmid retention. Moreover, after several weeks, the
remaining GFPdnLMP1 positive cells showed evidence of
undergoing apoptosis. With the loss of GFPdnLMP1
expression from the selected population, no expressing
clones could be isolated. This is not to say that escape
mutation is not possible in these B-cells, but perhaps
occurs at too low a frequency to have been isolated in
these assays.
Human EBV-associated tumours may have a more
complex etiology than the transgenic tumours described
here and indeed, several EBV-associated tumours show
absolutely no expression of LMP1. However, in those
EBV-associated tumours that do show LMP1 expression
(if not consistently), like NPC and HD, it is reasonable to
conclude from the wealth of data available on LMP1
activity, that it has been factorial in the development of
the tumour, as it has in these transgenic mouse tumours.
The data described here show that LMP1 continues to
provide a growth advantage in established tumours even
when expressed at very low level and provide proof of
principle that in these tumour types LMP1 directed ther-
apy could be effective.
Conclusions
Generally, therapeutic drug resistance emerges following
cancer treatments as a function of the number of tumour
cells at the time of treatment as well as their potential
ability to overcome the treatment. As a viral protein
LMP1 diverts cellular processes to affect an altered
g r o w t h  p r o g r a m m e  o f  t h e  c e l l  a n d  b y  s e c r e t i o n  o f
induced factors, alter the cellular environment. It is not a
cellular product and therefore not fundamentally essen-
tial to the cell. There are likely to be multiple mutational
routes (of cellular genes) which could compensate for the
loss of LMP1 function in the tumour cell and thus multi-
ple possible routes for resistant cells to emerge following
any LMP1 directed therapy. However, our results suggest
that inhibition of LMP1 could be highly effective with
some tumours and possibly stall others, even in EBV
associated cancer types where detection of LMP1 is
inconsistent, such as NPC. If combined with cytoto xic
drugs, targeting LMP1 action could improve outcome in
both epithelial and B-cell tumours.
Methods
EμLMP-1 and PyLMP1 transgenic lines and tumours
Transgenic mouse line EμLMP1 line 39 (EμLMP1.39),
expressing low levels of LMP1 in the lymphoid compart-
ment has been used in the studies described herein [3],
maintained in the C57Bl/6 strain. Mice of this line
develop lymphoma at an average age of approximately 20
months (supplementary information figure 1). Lym-
phoma incidence in the transgenic mouse line EμEBNA-
1.59 expressing EBNA-1 in the lymphoid compartment,
has been previously described [17]. Mice of line
PyLMP1.53 (LMP1 of the EBV B95-8) express LMP1 in
the epidermis and are maintained in the FVB mouse
strain [3,13]. Carcinomas were induced in PyLMP1.53Hannigan and Wilson Molecular Cancer 2010, 9:184
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mice using a standard single dose DMBA followed by 20
week TPA topical chemical carcinogen regime as previ-
ously described [13,18].
Cell lines
Cell line 39.415 was developed following sequential in
vivo  passage of a B-cell tumour arising in mouse
EμLMP1.39 number 415. After 3 passages in B6D2 strain
immunocompetent mice, the tumour could be estab-
lished in culture (supplementary information). Cell line
3959.48, expressing both LMP1 and EBNA-1 was estab-
lished in culture following explant of a B-cell lymphoma
from a bitransgenic mouse of the lines EμLMP1.39 and
EμEBNA-1.59. B-cell lines were grown in RPMI supple-
mented with 10% FCS, 2 mM glutamine, 100 units/ml
penicillin/streptomycin. Carcinoma cell lines were devel-
oped from primary carcinomas as described [13], grown
in DMEM containing 10% FCS, 2 mM glutamine, 100
units/ml penicillin/streptomycin. CarB is a spindle-cell
carcinoma cell line derived from a wild type mouse fol-
lowing DMBA/TPA chemical carcinogen treatment [19].
Raji is an EBV positive BL cell line, BL2B958 is an EBV
negative BL cell line subsequently infected with EBV of
the B95-8 strain, AK31 is an EBV negative derivative of
the EBV positive Akata BL cell line.
Protein extraction and western blotting
Protease inhibitors (complete mini, Roche), 1 mM phe-
nylmethylsulfonyl fluoride and phosphatase inhibitors
(10 μl/ml, phosphatase inhibitor cocktail II, Sigma) were
freshly added to the protein extraction buffers. Proteins
were extracted according to one of three protocols: [1]
using urea protein extraction buffer (8M urea, 25 mM
tris-HCl pH9.5, 5% (v/v) 2-mercaptoethanol), with incu-
bation at 55°C overnight with agitation; [2] using RIPA
buffer (150 mM NaCl, 50 mM tris-HCl pH7.5, 1% (v/v)
triton, 1% (w/v) deoxycholic acid, 0.1% (w/v) SDS) fol-
lowed by sonication; [3] alternatively counted cells were
resuspended in PBS with protease inhibitors and soni-
cated and an equal volume of 2 × boiling mix was added
(1 × boiling mix: 62.5 mM tris-HCl pH6.8, 2% (w/v) SDS,
5% (v/v) 2-mercaptoethanol, 10% (v/v) glycerol, trace bro-
mophenol blue), heated to 95°C for 5 minutes for direct
gel loading. Protein concentration was determined by
B r a d f o r d  a s s a y  ( B i o r a d )  o r  b y  2 D  Q u a n t  a s s a y  ( G E
Healthcare). For SDS-PAGE, boiling mix was added to a
1× concentration to protein aliquots which were heated
to 95°C for 5 minutes and loaded on to gels of 7.5%, 10%
or 12.5%. Gels were blotted and blots were probed and
washed as previously described [18]. Blots were incu-
bated in 5% non-fat milk, 0.1% (v/v) Tween 20 in PBS
with either 1:1000 anti β-tubulin (sc-9104, Santa Cruz),
1:100 1G6 (anti-LMP1) [20] or 1:500 anti-GFP (sc-8334,
Santa Cruz) followed by 1:4000 of the appropriate IgG-
HRP-conjugated secondary antibody (anti-rabbit sc-
2030, anti-rat sc-2032 Santa-Cruz) and visualized by
enhanced chemiluminescence (liteAblot kit, Euroclone).
Immunoprecipitation
Equal quantities of urea-extracted protein samples were
diluted at least 10-fold and made up to a total volume of 1
ml with NET-N pH8.0 (150 mM NaCl, 5 mM EDTA pH8,
50 mM tris-HCl pH8, 0.05% (v/v) NP-40) including pro-
tease and phosphatase inhibitors. To pre-clear, 70 μl of
50% (v/v) protein sepharose G (pre-washed) in NET-N
buffer was added to each of the samples and rotated at
4°C for 2 hours. The samples were centrifuged at 10000 g
for 10 mins at 4°C, and the pre-clear step was repeated
with the supernatant using 30 μl of 50% (v/v) protein sep-
harose G. 4 μl of anti-LMP1 S12 [21] was added to the
pre-cleared supernatant and rotated at 4°C overnight. 30
μl of 50% (v/v) protein sepharose G was added to each
sample and rotated at 4°C for 30 mins. The samples were
centrifuged at 10000 g for 10 mins at 4°C and the pellet
was washed with 1 ml of NET-N pH8.0, followed by 1 ml
of PBS with centrifugation at 10000 g for 1 min at 4°C.
The antibody-antigen complexes were eluted from the
beads with 30 μl of boiling mix at 95°C for 5 mins and
centrifuged at 10000 g for 1 min prior to SDS-PAGE.
Plasmids and transfection
The dominant-negative LMP1 plasmid pGFPdnLMP1
encoding an LMP1AAAG mutant in which codons 204,
206, 208 and 384 have been changed from amino acids P,
Q, T and Y to A, A, A and G and linked at the N-terminus
to an in-frame enhanced-GFP tag, under the control of
the CMV promoter, has been previously described [16]. It
is abbreviated to dnL for cell subclones transfected with
the plasmid. As control, pEGFP-C1 (Clontech) (abbrevi-
ated here to pGFP) encoding enhanced-GFP under the
control of the CMV promoter has been used. B cells (typ-
ically 1 × 107) were transfected with 10 μg of plasmid
DNA by electroporation (960uF, 250 V), or "no DNA" as
control, using a Biorad electroporater or an Amaxa nucle-
ofector with solution V. One day after transfection cells
were subjected to G418 selection (supplementary infor-
mation table 1) and regarded as stably transfected (or
post the selective process) when all no DNA controls cells
were dead (2 to 3 weeks post transfection). Post selection
cells were continually maintained in G418 thereafter. Epi-
thelial cell lines were transfected in duplicate with either
superfect (Qiagen) or metafectene lipid-based transfec-
tion reagents according to the manufacturer's instruc-
tions. Typically, one day after transfection cells were split
1:8 and then subjected to selection which was usually
complete by 2 weeks (supplementary information table
1). Post selection clones were continually maintained in
G418 thereafter.Hannigan and Wilson Molecular Cancer 2010, 9:184
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Clonagenicity assay with crystal violet
C e l ls  we r e  p la t ed in 6 cm  dis hes,  t ra ns f ect ed wit h t he
appropriate plasmid and selected with G418. 14 days
post-transfection, surviving colonies were stained with
crystal violet solution (0.5% (w/v) crystal violet, 20% (v/v)
ethanol in dH2O) at RT for 10 mins to 1 hour, washed
gently with tap water and allowed to dry. The number of
clones on each plate was counted directly.
Cell growth assay with neutral red
Cells were seeded at a density of 500 cells per well (in
quadruplicate sets for each daily count) in 96-well plates
in 100 μl of medium. At daily intervals, cells were treated
as follows: the medium was replaced in the wells to be
analysed with pre-warmed neutral red-containing (40 μg/
ml) medium and incubated at 37°C, 5% CO2 for 3 hours.
The medium was removed, the cells were fixed with 100
μl of 1% (w/v) CaCl2, 0.5% (v/v) formaldehyde which was
then removed and 100 μl of 1% (v/v) acetic acid 50% (v/v)
ethanol was added to each well in order to liberate the
dye from the viable cells that had incorporated stain. The
plate was incubated at RT for 10-15 mins, rocked for 20-
30 mins, then neutral red containing solutions were
transferred to an empty plate and the absorbance was
measured at 540 nm. Cells were assayed up to confluence
(6 to 8 days). Statistical difference was calculated using a
two sample T-test assuming equal variances.
Flow cytometry
Cells were analysed using a FACScalibur flow cytometer
(Becton Dickinson). Data was collected and analysed
using CellQuest software (Becton Dickinson). Where
possible, 10000 events (or GFP positive cells) were analy-
sed. For GFP analysis cells were counted, washed twice
with PBS and resuspended at 2 × 106 cells/ml in PBS prior
to FACS analysis. Apoptosis was assessed by propidium
iodide exclusion; cells were counted, washed twice with
PBS and resuspended at 2 × 106 cells/ml in PBS. Typically
2 × 106 to 1 × 107 cells were used. Immediately prior to
FACS analysis, 10 μl of 50 mg/ml propidium iodide (PI)
solution was added per 1 ml of cell suspension.
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